Background: Alcohol-related liver disease (ALD) represents a major cause of death worldwide, and unfortunately, most patients are diagnosed at an advanced stage of the disease, which is related to poorer outcomes. Liver biopsy has historically been the gold standard for identifying advanced hepatic fibrosis, but this approach has several limitations, including invasiveness, low applicability, sampling variability, and cost.
steatosis is present in almost all heavy drinkers, only 8% to 20% of these patients will ultimately develop cirrhosis. 10 However, a recent study reported that 73% of patients admitted to the hospital for the first time with cirrhosis or liver failure were unaware of their condition, suggesting that most patients are diagnosed at a decompensated stage or advanced disease. 11 Furthermore, it seems that ALD is rarely detected at early stages compared with liver diseases of other etiologies. 12 Since fibrosis is the major predictive factor of long-term survival in compensated patients, 12 its detection is crucial before decompensation (which is associated with a poorer prognosis 13, 14 ) in order to promote the reduction and, ideally, complete withdrawal, of alcohol consumption.
Considering that in its earlier stages, ALD is a silent disease, screening tools to identify individuals with alcohol use disorders (AUDs) and tests to detect liver fibrosis must be implemented, particularly among general practitioners and psychiatric units. Although liver biopsy is still the gold standard for estimating liver fibrosis, 15 it cannot be proposed as a screening tool due to the risk of complications and cost. 15 Therefore, while initially developed in chronic hepatitis C and NAFLD, 16, 17 noninvasive tests have become increasingly used in clinical practice in order to evaluate the severity of liver fibrosis in other etiologies of liver disease. They have proven to have not only an excellent predictive value for diagnosis of advanced fibrosis but also an adequate prognostic value. 18 This review article focuses on screening and noninvasive diagnostic tools for the detection of liver fibrosis in patients with ALD and their importance in clinical practice. We will also briefly summarize novel biomarkers currently being investigated as well as future directions and new opportunities in the noninvasive diagnosis of ALD.
| THE CLINICAL PROBLEM: WHO AND HOW TO EVALUATE AND FOLLOW FOR ALD?
2.1 | Who should we screen?
Data are conflicting regarding the definition of a safe alcohol limit, with no clear threshold effect. 19 Interestingly, the old statement that moderate alcohol consumption is protective for ischemic heart disease and diabetes in women was recently counterbalanced by a worldwide comprehensive study that assessed estimations of alcohol use, alcohol attributable deaths, and disability-adjusted lifeyears. 19 It was reported that the level of consumption that minimizes an individual's risk is 0 g of ethanol per week. This threshold is likely related to the risk of cancer associated with alcohol consumption, which is based on a linear dose relationship, 20, 21 whereas for liver diseases, the relationship is exponential. 20, 21 A meta-analysis 22 found that the threshold associated with increased risk of mortality from liver cirrhosis among men and women is 12 to 24 g of ethanol per day. Beyond the specific amount of alcohol, drinking patterns are also an issue, with daily and binge drinking also being associated with a higher risk of liver cirrhosis. [23] [24] [25] Furthermore, competing risk factors must be taken into account when considering the thresholds of >30 g/d for men and >20 g/d for women used in daily clinical practice. 5 Among these, obesity, in addition to being an independent factor associated with ALD progression, 26 when associated with a body mass index (BMI) > 30, is not only additive but also synergistic.
One study that assessed obese patients with excess drinking (more than 15 drinks per week) compared with lean patients with the same drinking pattern revealed that the adjusted relative rates for liver disease mortality were 18.9 (95% CI, 6.84-52.4) and 3.16 (95% CI, 1.28-7.8), respectively. 27 Similarly, components of the metabolic syndrome, such as type 2 diabetes and/or insulin resistance, are also independent predictors of liver-related mortality in ALD. 28 Furthermore, a recent study has evaluated the association between early age alcohol consumption and the occurrence of severe liver disease. 29 Surprisingly, there was no threshold effect, the risk was dose dependent, and alcohol consumption in early age was associated with an increased risk of severe liver disease. Lastly, lower socioeconomic status has also been associated with a higher risk of mortality from ALD, 30, 31 although the underlying explanatory factors for this finding are not yet fully understood. Collectively, as highlighted, the commonly used threshold effect is inaccurate by itself, and we should likely lower the drinking limit in patients who present with comorbid factors.
Finally, screening for harmful alcohol consumption should be done in primary care and other health and community settings in order to deliver effective intervention, 5 even though the long-term effects of screening on abstinence and relapse still need to be determined with real-life data.
| How do we screen?
Noninvasive methods to detect liver fibrosis rely on two different approaches: the biological approach based on the quantification of biomarkers in serum samples and a physical approach based on the measurement of liver stiffness (LS) using imaging techniques. These two approaches will be described below.
As highlighted previously, considering the fact that liver fibrosis is the major predictor of long-term survival, we will focus on this aspect in this review, and diagnosis and evaluation of liver steatosis in ALD will not be discussed in this article.
| Biological tests
Several nonpatented and patented serum biomarkers (Table 1) 32 The FT score is based on an algorithm calculated from six serum markers, whereas the ELF test integrates three direct serum markers of extracellular matrix remodeling and fibrogenesis, namely, hyaluronic acid, tissue inhibitor of metalloproteinase-1, and N-terminal propeptide for collagen type III. 35 The latter is considered to be a direct marker of fibrosis, since it provides a direct measurement of the degree of extracellular material deposition. 35 The reproducibility and performance of the ELF score was initially evaluated in a large cohort of patients with chronic liver disease with mixed etiologies, 35 and a recent Danish study 32 has confirmed the high accuracy of the ELF test, showing that it is similar to FT in the assessment of liver fibrosis in ALD (area under the ROC curve [AUROC] of 0.92 and 0.90, respectively). Among other patented biomarkers, Fibrometer and Hepascore show comparable accuracy that does not differ from that of FT in patients with ALD. 33 Although the above-mentioned patented biomarkers and FT showed similar accuracy in the prediction of advanced fibrosis and cirrhosis, in a multivariate analysis, FT alone was the most informative biomarker in terms of diagnostic and prognostic performance. Despite their excellent accuracy, these patented tests lack widespread applicability due to their high costs.
Nonpatented serum biomarkers have also been assessed in ALD.
Aspartate transaminase-platelet ratio index (APRI) includes AST and platelet count as variables and has been assessed in 507 patients with ALD. 36 APRI values >1.5 had a sensitivity and specificity of 13.2% and 77.6%, respectively, for the diagnosis of significant fibrosis, whereas a cutoff >2 had a sensitivity and specificity for the diagnosis of cirrhosis of 16.9% and 86.4%, respectively, 36 suggesting a lack of clinical utility. This low diagnostic performance was also established in a Danish prospective study that evaluated the accuracy of direct and indirect biomarkers. 32 Similarly, the fibrosis-4 (Fib-4) score also demonstrated low diagnostic performance, with AUROCs for advanced fibrosis, significant fibrosis, and cirrhosis of 0.85, 0.77, and 0.89, respectively. 32 Altogether, despite their higher cost compared with nonpatented and other patented serum biomarkers, the FT and ELF tests provide the best diagnostic and prognostic performance to date in the identification of advanced liver fibrosis. Additionally, these biomarkers (in particular, the ELF test) are highly cost-effective and should be tested in primary health care settings. 37, 38 Lastly, advanced fibrosis can be ruled out in primary health care patients with an ELF value <10.5 or an FT < 0.58. 32 Therefore, these tests might be helpful in reducing the need for liver biopsy.
| Transient elastography
One-dimensional ultrasound transient elastography (TE), or Fibroscan (Echosens, Paris, France), is a physical approach aimed at measuring the velocity of a low-frequency (50 Hz) elastic shear wave spreading through the liver. 39 This velocity is directly related to LS, such that the stiffer the tissue, the faster the shear wave spreads. Shear wave velocity is then converted into a liver stiffness measurement (LSM).
This technique has numerous advantages, such as a short procedure time (<5 min), immediate results, ability to perform the procedure at the bedside or in an outpatient clinic, well-defined quality criteria, and good reproducibility. 40 Furthermore, it has been demonstrated that the learning curve is reasonable 41 and that the minimal training required to be able to perform the test is about 100 exams. Although the methodology has excellent interobserver and intraobserver agreement (intraclass correlation coefficient of 0.98), 40, 42 its applicability is lower compared with serum biomarkers. In a French study evaluating the reliability (defined as fewer than 10 valid shots) and failure rate (defined as zero valid shots) of more than 13 369 examinations, 43 LSM failure and unreliable results occurred in 3.1% and 15.8% cases, respectively, whereas the mean applicability rate of FT was 99.03%. 44 However, despite the failure rate of TE, it still outperformed liver biopsy, which has been associated with a sampling error of nearly 30%. [45] [46] [47] [48] Nevertheless, even if TE is an excellent surrogate marker of advanced fibrosis and cirrhosis, it has some limitations, and confounding variables must be addressed to ensure the correct interpretation of results obtained from TE. The main confounders to be taken into consideration are nonfasting, [49] [50] [51] inflammation, 52, 53 inexperience, 41, 43 congestion, 54, 55 alcohol, 56 obesity, 43, 57 cholestasis, 58 amyloidosis, 59 and alcoholic hepatitis (AH) 60 ( Table 2 ).
However, for obese patients, an XL probe has been developed, 66 which can result in reduced TE failure and improved reliability of LSM, but it must be kept in mind that LS cutoffs are lower with the XL probe. Additionally, these LS cutoffs must also be adjusted to the AST level. This feature was initially observed in viral hepatitis, where LSM correlated positively with transaminase levels, 67, 68 and later on, in commercial ultrasound machines and lower rates of failure compared with TE, as well as better performance in patients with ascites and obesity 81 (Table 2) . Similarly to TE, ARFI measurements are influenced by food intake and AST levels. 63, 64 A recent meta-analysis 82 Lastly, magnetic resonance elastography (MRE) quantifies elasticity (expressed in kPa) using a formula that characterizes the shear modulus, which is equivalent to one-third of the Young modulus used with TE. 83, 84 It has also been evaluated in a meta-analysis (mostly viral hepatitis and NAFLD) based on 12 retrospective studies, comprising 697 patients. 65 The diagnostic accuracy of any fibrosis, significant fibrosis, advanced fibrosis, and cirrhosis was 0.84, 0.88, 0.93, and 0.92, respectively, with an overall failure rate of 4.3% (Table 2 ). In a head-tohead comparison between 3D-MRE vs 2D-MRE, 3D-MRE was superior to 2D-MRE, with an AUROC for the detection of advanced fibrosis of 0.98 (3D-MRE) vs 0.92 (2D-MRE). 85 Unfortunately, its implementation in daily clinical practice is rather difficult due to the higher cost, the time consumed by the procedure, and the low availability of MR machines, ultimately resulting in lower applicability.
| Use in clinical practice
In patients with suspected ALD (presence of AUD, abnormal liver tests with AST/ALT >1, high levels of γ-glutamyltransferase 111 with permission from Elsevier approaches are complementary, the latter is more suited as a screening tool given the local availability in primary health care. Figure 1 depicts our proposed algorithm for the use of noninvasive methods for risk stratification of patients with ALD in clinical practice. AUD should be screened in primary health care, alcohol rehabilitation centers, and in psychiatric units, since the prevalence of AUD is higher in patients with psychiatric disorders. 87 In order to increase the identification of AUD and to better characterize patients' drinking habits, screening tools have been developed, including one of the most validated and widely used, the Alcohol Use Disorders Inventory Test (AUDIT). 88 For low prevalence populations, such as patients in the primary health care sector, serum biomarkers with high negative predictive value (>94%), such as the ELF score and FT, should be used as a first-line method to rule out advanced fibrosis.
Although patented biomarkers are considered to have lower applicability compared with nonpatented ones given their higher cost, two recent studies 37, 38 have found that the ELF score is cost-effective in primary health care 38 
| Why are noninvasive tests of clinical importance?
In addition to the excellent accuracy of noninvasive tests for the estimation of liver fibrosis, recent studies have shown that TE and serum biomarkers also have the ability to predict clinical decompensation as well as survival in patients with chronic liver disease. 90 Recently, "omics" approaches (lipidomics, proteomics, metabolomics, and transcriptomics) have shown promising results with regard to the identification of novel markers in NAFLD, 103 and some of these approaches are also currently being assessed in ALD. 104 In a mouse model of ALD, proteomic analysis of circulating extracellular vesicles (EVs) has shown a distinct signature of proteins as compared with control-EVs. 105 They have also identified Heat shock protein 90 in ALD-EVs as a mediator of macrophage activation. On the other hand, among transcriptomic approaches based on circulating small noncoding RNA (miRNA) and long-noncoding RNAs (lncRNAs), several exosome-associated miRNAs have been studied as potential biomarkers in preclinical studies. [106] [107] [108] [109] Briefly, in mouse models of ALD, serum levels of miR-155 and miR-122 110 were increased and, interestingly, enriched in circulating exosomes as well as miR-192 and miR-30a. 108 More importantly, the latter finding has also been confirmed in patients with AH compared with healthy controls. 108 Lastly, lncRNAs, such as AK128652 and AK054921, were also increased in the sera of patients with alcoholic cirrhosis and seem to be surrogate markers for survival in these patients. 109 Overall, these promising biomarkers are still in the field of translational research, and larger trials to evaluate their accuracy and feasibility are needed.
Finally, the diagnostic abilities of noninvasive markers for ALD must also be assessed in primary care since the prevalence in this population might be different compared with that in secondary and tertiary care settings and could negatively impact the sensitivity and negative predictive value of these surrogate markers of liver fibrosis.
| CONCLUSION
Significant progress has been made in the noninvasive assessment of liver disease in patients with ALD. Regarding the identification of advanced fibrosis, ELF score, FT, and TE are the most accurate and validated modalities. These patented biomarkers are best suited for first-line investigation in primary care since they have been shown to be cost-effective, but additional external validation is needed. TE is well-suited for second-line investigation in referral centers in order to select patients who might require liver biopsy or need follow-up in the liver clinic. The performance of other imaging techniques (ARFI, 2D-SWE, and MRE), although promising, needs to be better assessed in patients with ALD, with an accurate definition of quality criteria. Initially developed for diagnostic purposes, these noninvasive modalities seem to also have prognostic value in terms of prediction of overall survival, clinical decompensation, and HCC occurrence, but future long-term studies will help us determine more accurately the role for these markers in the prognosis of patients with ALD. Efforts need to be concentrated on the development of novel biomarkers and, primarily, on the implementation of noninvasive diagnostic modalities in primary care, in order to identify patients earlier, before decompensation, which is associated with poorer outcomes. Finally, considering the growing burden of liver disease worldwide, a great challenge resides in the establishment of efficient public health policies that aim to reduce harmful alcohol consumption as well as to improve accessibility to interventions that allow us to reach this goal.
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